Table 3.
Five-year cumulative detection (risks) for CIN3, AIS, or cancer (CIN3+) and for cervical cancer for human papillomavirus (HPV)-positive or cytology-positive (atypical squamous cells of undetermined significance or more severe [ASC-US+]) results for the first, second, third, and fourth co-test following 0–3 consecutive negative co-test(s), respectively
| Co-test result | Co-test No.† | Total, No. | CIN3+ |
Cervical cancer* |
||
|---|---|---|---|---|---|---|
| No. | 5-year risk‡, % (95% CI) | No. | 5-year risk‡, % (95% CI) | |||
| HPV positive§ | 1 | 58 446 | 3379 | 7.2 (7.0 to 7.4) | 245 | 0.5 (0.4 to 0.6) |
| HPV positive§ | 2 | 16 972 | 395 | 3.0 (2.7 to 3.4) | 19 | 0.1 (0.09 to 0.2) |
| HPV positive§ | 3 | 6290 | 98 | 2.3 (1.9 to 2.9) | 3 | 0.05 (0.04 to 0.1) |
| HPV positive§ | 4 | 1803 | 11 | 1.5 (0.7 to 3.4) | — | — |
| ASC-US+‖ | 1 | 44 861 | 2480 | 6.6 (6.4 to 6.9) | 199 | 0.5 (0.4 to 0.6) |
| ASC-US+‖ | 2 | 18 765 | 310 | 2.0 (1.8 to 2.3) | 17 | 0.1 (0.07 to 0.2) |
| ASC-US+‖ | 3 | 6765 | 72 | 1.5 (1.2 to 1.9) | 2 | 0.03 (0.01 to 0.1) |
| ASC-US+‖ | 4 | 2073 | 11 | 1.1 (0.5 to 2.3) | — | — |
Estimates of cervical cancer risk for the fourth co-test were not included because of small numbers of women overall and no cervical cancers were diagnosed. ASC-US+ = atypical squamous cells of undetermined significance or more severe cytological interpretations.
The co-test was preceded by the co-test number-1 of negative co-tests.
Risk estimates for HPV positive, ASC-US+, and HPV-negative ASC-US+ were obtained by estimating risks within subpopulations grouped by screening protocols. Point estimates are a weighted average of subpopulation risks, weighted by the frequency in which they occur. Confidence intervals are derived by using survey methodology approaches to combine the variance estimates of the subpopulation risks.
HPV positive regardless of the cytology result.
Cytology positive regardless of the HPV result.